Business · 18/05/1999Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for Lotemax and Alrex Patent Extensions
Summary
The FDA has officially confirmed the review period for patent extensions for Lotemax and Alrex, two human drug products, following a submission to the US Patent and Trademark Office.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →